HRP20020091B1 - ?-carboline drug products - Google Patents

?-carboline drug products

Info

Publication number
HRP20020091B1
HRP20020091B1 HR20020091A HRP20020091A HRP20020091B1 HR P20020091 B1 HRP20020091 B1 HR P20020091B1 HR 20020091 A HR20020091 A HR 20020091A HR P20020091 A HRP20020091 A HR P20020091A HR P20020091 B1 HRP20020091 B1 HR P20020091B1
Authority
HR
Croatia
Prior art keywords
carboline
drug products
compound
particles
coprecipitate
Prior art date
Application number
HR20020091A
Other languages
English (en)
Croatian (hr)
Inventor
Neil
Kerry
Martha
Gregory
Original Assignee
Lilly Icos Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22520112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20020091(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Icos Llc filed Critical Lilly Icos Llc
Publication of HRP20020091A2 publication Critical patent/HRP20020091A2/hr
Publication of HRP20020091B1 publication Critical patent/HRP20020091B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20020091A 1999-08-03 2002-01-29 ?-carboline drug products HRP20020091B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14704899P 1999-08-03 1999-08-03
PCT/US2000/020981 WO2001008688A2 (en) 1999-08-03 2000-08-01 Beta-carboline drug products

Publications (2)

Publication Number Publication Date
HRP20020091A2 HRP20020091A2 (en) 2004-02-29
HRP20020091B1 true HRP20020091B1 (en) 2006-02-28

Family

ID=22520112

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020091A HRP20020091B1 (en) 1999-08-03 2002-01-29 ?-carboline drug products

Country Status (33)

Country Link
EP (1) EP1200092B1 (xx)
JP (1) JP4456788B2 (xx)
KR (1) KR20020063842A (xx)
CN (2) CN1377270A (xx)
AR (1) AR033953A1 (xx)
AT (1) ATE264680T1 (xx)
AU (1) AU773666B2 (xx)
BR (1) BR0012901A (xx)
CA (1) CA2380087C (xx)
CO (1) CO5200849A1 (xx)
CZ (1) CZ300151B6 (xx)
DE (1) DE60010089T2 (xx)
DK (1) DK1200092T3 (xx)
DZ (1) DZ3180A1 (xx)
EA (1) EA004302B9 (xx)
ES (1) ES2220506T3 (xx)
HK (1) HK1044278B (xx)
HR (1) HRP20020091B1 (xx)
HU (1) HU229443B1 (xx)
IL (1) IL147642A0 (xx)
MX (1) MXPA02001197A (xx)
MY (1) MY125428A (xx)
NO (1) NO321602B1 (xx)
NZ (1) NZ516613A (xx)
PE (1) PE20010480A1 (xx)
PL (1) PL199469B1 (xx)
PT (1) PT1200092E (xx)
SK (1) SK286365B6 (xx)
SV (1) SV2002000137A (xx)
TW (1) TWI235658B (xx)
UA (1) UA71629C2 (xx)
WO (1) WO2001008688A2 (xx)
ZA (1) ZA200200825B (xx)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287869B6 (sk) * 1999-08-03 2012-02-03 Icos Corporation Beta-carboline pharmaceutical compositions
EP2216329A1 (en) * 2004-10-28 2010-08-11 Dr. Reddy's Laboratories Ltd. Processes for the preparation of tadalafi
DE602006004694D1 (de) * 2006-01-05 2009-02-26 Teva Pharma Feuchtgranulierungsmethode zur Herstellung pharmazeutischer Aripiprazolzusammensetzungen
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
DE102009035211A1 (de) 2009-07-29 2011-02-17 Ratiopharm Gmbh Copräzipitate umfassend einen Phosphodiesterase-5-Inhibitor (PDE-5-Inhibitor) und einen pharmazeutisch verträglichen Trägerstoff, ihre Herstellung und Verwendung
WO2012085927A2 (en) * 2010-12-02 2012-06-28 Mylan Laboratories, Limited Tadalafil compositions
WO2012095151A1 (en) 2010-12-23 2012-07-19 Zaklady Farmaceutyczne Polpharma Sa Solid pharmaceutical dosage forms comprising tadalafil and methods of preparation thereof
RU2013141446A (ru) 2011-02-10 2015-03-20 Синтон Бв Фармацевтическая композиция, содержащая тадалафил и циклодекстрин
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
JP5930686B2 (ja) * 2011-12-07 2016-06-08 株式会社トクヤマ 溶解性および安定性の向上した難溶性医薬品原体及びその製造方法
US9871201B2 (en) 2012-03-15 2018-01-16 Merck Patent Gmbh Electronic devices
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2014003677A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising solid dispersion particles containing tadalafil
CN105310984A (zh) * 2014-06-10 2016-02-10 合肥贝霓医药科技有限公司 一种pde5抑制剂的超微粉体及其制备方法
EP3111929B1 (en) * 2014-06-24 2018-08-29 Wooshin Labottach Co., Ltd. Oral disintegrating film formulation containing tadalafil and preparation method therefor
SI3466951T1 (sl) 2014-07-23 2022-05-31 Krka, D.D., Novo Mesto Proces za pripravo zaviralca CGMP-fosfodiesteraze in oralne farmacevtske formulacije, ki obsega koprecipitate tadalafila
JP2016106139A (ja) * 2016-03-07 2016-06-16 株式会社トクヤマ 溶解性および安定性の向上した難溶性医薬品原体及びその製造方法
US11464778B2 (en) * 2017-12-26 2022-10-11 Liqmeds Worldwide Limited Liquid oral formulations for sildenafil
EP3510997B1 (en) 2018-01-10 2020-08-05 Gap S.A. Soft gelatin capsules comprising a suspension of tadalafil
CN110638770B (zh) * 2019-10-25 2022-04-05 株洲千金药业股份有限公司 他达拉非片剂的制备方法及以该方法制得的片剂
WO2023227185A1 (en) 2022-05-27 2023-11-30 Rontis Hellas S.A. Improved pharmaceutical composition containing tadalafil and nanomilling process for the preparation thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618845A (en) * 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions

Also Published As

Publication number Publication date
JP4456788B2 (ja) 2010-04-28
DK1200092T3 (da) 2004-08-16
ATE264680T1 (de) 2004-05-15
CZ300151B6 (cs) 2009-02-25
CO5200849A1 (es) 2002-09-27
EP1200092B1 (en) 2004-04-21
PT1200092E (pt) 2004-07-30
PL199469B1 (pl) 2008-09-30
EP1200092A2 (en) 2002-05-02
CA2380087A1 (en) 2001-02-08
HK1044278A1 (en) 2002-10-18
NO321602B1 (no) 2006-06-12
KR20020063842A (ko) 2002-08-05
PE20010480A1 (es) 2001-05-26
NO20020531L (no) 2002-04-03
WO2001008688A2 (en) 2001-02-08
SK1722002A3 (en) 2002-05-09
BR0012901A (pt) 2002-04-16
ZA200200825B (en) 2003-04-30
CN101134019A (zh) 2008-03-05
HK1044278B (zh) 2004-10-08
DE60010089D1 (de) 2004-05-27
HRP20020091A2 (en) 2004-02-29
IL147642A0 (en) 2002-08-14
WO2001008688A3 (en) 2001-08-16
CN1377270A (zh) 2002-10-30
SK286365B6 (sk) 2008-08-05
ES2220506T3 (es) 2004-12-16
AR033953A1 (es) 2004-01-21
EA004302B9 (ru) 2019-01-31
DZ3180A1 (fr) 2001-02-08
JP2003505510A (ja) 2003-02-12
CA2380087C (en) 2007-05-01
HUP0202781A3 (en) 2003-10-28
MXPA02001197A (es) 2003-02-12
EA004302B1 (ru) 2004-02-26
NZ516613A (en) 2003-08-29
AU6508400A (en) 2001-02-19
HU229443B1 (en) 2013-12-30
UA71629C2 (en) 2004-12-15
EA200200119A1 (ru) 2002-06-27
SV2002000137A (es) 2002-06-07
HUP0202781A2 (hu) 2002-12-28
NO20020531D0 (no) 2002-02-01
DE60010089T2 (de) 2004-10-14
PL353268A1 (en) 2003-11-03
TWI235658B (en) 2005-07-11
AU773666B2 (en) 2004-06-03
CZ2002387A3 (cs) 2002-10-16
MY125428A (en) 2006-07-31

Similar Documents

Publication Publication Date Title
HRP20020091B1 (en) ?-carboline drug products
GEP20053474B (en) Glucocorticoid Receptor Modulators
GEP20053614B (en) Compositions for Oral Administration Containing Opioid Agonist
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
PT1041987E (pt) Forma farmaceutica de dosagem oral, compreendendo uma combinacao de um agonista de opioide e naltrexona
CA2346001A1 (en) Controlled release nanoparticulate compositions
IL111647A0 (en) Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles, their preparation and pharmaceutical compositions containing them
MY135852A (en) Pharmaceutical products
GEP20012388B (en) Metalloproteinase Inhibitors, Pharmaceutical Compositions on Their Base, Use and Methods for Obtaining and Intermediates
GB9717576D0 (en) Pharmaceutical compounds
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
BG104877A (en) N-substituted anminotetralins as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
YU26102A (sh) Nove farmaceutske smese antituberkuloznih lekova i postupak za njihovo dobijanje
AU1340699A (en) Hyperbranched polymers or dendrimers having a particular group, preparation method and compositions containing same
ME00416B (me) Celekoksibne smješe
DE69905380D1 (de) Pharmazeutische zusammensetzungen mit schneller freisetzung von wirkstoffen
DK1553927T3 (da) Gel-stabiliserede, nanopartikulære aktivstof-sammensætninger
DE602005027477D1 (de) Arzneimittelabgabe aus embolischen mitteln
HUP0202757A3 (en) Heteropolycyclic compounds, pharmaceutical compositions containing them and their use as metabotropic glutamate receptor antagonists
WO2003013433A3 (en) Sequestered antagonist formulations
NZ324887A (en) Piperazine and piperidine compounds with analgesic effect
BR9902268A (pt) Formulações de ziprasidona.
ATE68966T1 (de) Arzneidosisform fuer die mundhoehle.
HRP20080410A2 (en) Crystalline composition containing escitalopram
MX9505064A (es) Composicion farmaceutica, aplicable oralmente.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
PPPP Transfer of rights

Owner name: ICOS CORPORATION, US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20190723

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20200801